Molecules in pathogenesis: angiotensin converting enzyme 2 (ACE2)

Owen Wiese,1 Annalise E Zemlin,1 Tahir S Pillay 2,3

ABSTRACT

The renin–angiotensin system is mainly associated with the regulation of blood pressure, but recently many other functions of this system have been described. ACE2, an 805-amino acid monocarboxypeptidase type I transmembrane glycoprotein, was discovered in 2000 and has sequence similarity to two other proteins, namely ACE and collectrin. The ACE2 gene is located on Xp22 and is highly polymorphic. ACE2 is expressed in numerous tissues especially the lung alveolar epithelial cells, heart, kidney and gastrointestinal tract. Animal studies have found that ACE2 is central in diseases affecting almost all organ systems, among other cardiac, respiratory, renal and endocrine functions. ACE2 was identified as the cellular contact point for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the global pandemic (COVID-19), and is a potential drug target. SARS-CoV-2 infection has several effects on the renin–angiotensin system and conversely, regulation of this receptor may affect the progress of infection. We describe the genetics and functions of ACE2, explore its various physiological functions in the renin–angiotensin system and discuss its role in the pathophysiology of disease. ACE2 opposes the vasopressor ACE pathway of the renin–angiotensin system by converting angiotensin (Ang) I to Ang (1–9) and Ang II to Ang (1–7) which initiates the vasodilatory pathway. ACE2 may have a protective effect in the lung and kidney as knockout mice display susceptibility to acute respiratory distress and hypertensive nephropathy. Binding of SARS-CoV-2 and the subsequent fusion and downregulation of this pathway during SARS-CoV-2 infection may explain some of the unusual sequelae seen in COVID-19.

INTRODUCTION

Not since its discovery in 2000,1 2 has the ACE2 receptor attracted as much attention as currently. The receptor has been identified as the cellular docking point for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),3 the causative agent of COVID-19,4 which was declared a pandemic by the WHO5 and at the time of writing was responsible for >10 million cases and more than 500,000 deaths.6

The renin–angiotensin system is a central mechanism for blood pressure regulation through a diverse system of hormones and receptors (figure 1). The vasopressor actions of this ‘classical’ pathway is opposed by the actions of ACE2, a key component of the ‘protective (vasodilatory)’ arm which converts angiotensin (Ang) II to Ang (1–7). Thus, the system is central in a number of pathological processes ranging from cardiovascular and respiratory diseases, to amino acid absorption in the gut and kidney. Understanding the role of ACE2 has shed light on the pathogenesis of COVID-19 and may potentially explain the myriad of unusual biochemical findings.

ACE2 GENE

Location and gene product

ACE2 was discovered independently by two groups in 2000 by homology cloning from a heart failure ventricular complementary DNA (cDNA) library and a lymphoma cDNA library, respectively.1,2

The ACE2 gene is 39.98 kb in size, located on Xp22 and contains 18 exons and 20 introns.7 The gene is highly polymorphic8–10 and variations may account for differences in enzymatic activity.9 The gene undergoes alternative splicing to produce six variants.10

The final product is an 805 amino acid, 120kDa monocarboxypeptidase type I transmembrane glycoprotein. The first 17 amino acids make up the N-terminal signal peptide followed by a HEXXH zinc-binding metalloprotease motif, a C-terminal collectrin domain and an insulin-like domain that includes a ferredoxin-like neck domain ending with a 22 amino acid hydrophobic transmembrane region anchoring it in the cell membrane7 10 (figure 2).

Location on the X-chromosome implies that expression could be impacted by differences in parental imprinting and escape of X-inactivation in females resulting in dosage discordance in ACE2 expression between males and females.11 Interestingly, analysis of renin–angiotensin metabolites shows a 27% higher plasma renin activity in males.12 ACE2 shares significant sequence identity with two other proteins, ACE and collectrin (figure 3). Angiotensin converting enzyme

The significant homology, 42% amino acid sequence similarity in the catalytic domains, and the conservation of exon and intron organisation suggest that ACE and ACE2 genes originated from a common ancestor. The ACE gene is located on chromosome 17, spans 21 kb with 26 exons and 25 introns, and codes for a 180kDa protein anchored to the plasma membrane by a single carboxy-terminal transmembrane domain.13 Two differentially spliced forms are known. The single domain testicular form plays an important role in male fertility, and the two-domain somatic form is essential in regulating cardiovascular functions.14

Although it was initially thought that ACE and ACE2 have similar functions, this is not the case. The carboxypeptidase activity of ACE removes
**Figure 1** Central role of the renin–angiotensin system in blood pressure homeostasis. The cascaded system involves a number of enzymes and receptors. Angiotensinogen produced by the liver is converted to angiotensin I (Ang I) by renin secreted by the kidney. ACE2 is important in the conversion of Ang I to angiotensin (1–9) and angiotensin II (Ang II) to angiotensin (1–7). Ang II and angiotensin (1–7) exert a number of actions by binding to AT1, AT2 and MAS receptors. ACEi, ACE inhibitor; AT1, angiotensin type 1; AT2, angiotensin type 2.

**Figure 2** Gene structure of ACE2 compared with ACE and collectrin. HEMGH illustrates the zinc-binding motifs—the active sites of the protein. The exact locations of the genes are indicated. (Adapted from: Clarke and Turner).
the C-terminal dipeptide from the decapeptide Ang I to form the octapeptide Ang II. Ang II binds the angiotensin type 1 (AT1) receptors and has a well-established vasopressive role in regulating blood pressure (BP), fluid and electrolyte balance (via aldosterone).\textsuperscript{11} ACE inhibitors do not affect the ACE2 activity directly but may have indirect effects on ACE2 expression.\textsuperscript{15} Furthermore, ACE plays an important role in the kinin–kallikrein system by inactivating the vasodilator bradykinin.\textsuperscript{16}

Collectrin

Collectrin has 47.8% sequence similarity to the C-terminal region of ACE2 including the non-catalytic extracellular, transmembrane and cytosolic domains of the protein, but lacks the catalytic domain.\textsuperscript{17} Collectrin plays an important role in vesicle transport and membrane fusion. This is important in the exocytosis of insulin and other membrane proteins and is therefore an attractive possible treatment target for diabetes mellitus, polycystic kidney disease and hypertension.\textsuperscript{17} The collectrin gene is regulated by hepatocyte nuclear factor-1β, and disruption of this factor leads to maturity onset diabetes of the young (MODY) type 5 diabetes mellitus.\textsuperscript{17}

Sites of expression

ACE2 is expressed in a number of tissues but most abundantly in lung alveolar epithelial cells, kidney, heart, gastrointestinal tract and testes.\textsuperscript{13, 18} Soluble ACE2, a form lacking membrane anchors, is shed at very low levels into the circulation following the cleavage action of sheddases ADAM (A Disintegrin and Metalloprotease) 10 and ADAM 17 between amino acids 716 and 741. This form does not reflect tissue levels and has a very short half-life.\textsuperscript{19}
ROLE OF ACE2 IN PHYSIOLOGY AND PATHOPHYSIOLOGY

ACE2 regulates the levels of Ang I and Ang II by converting Ang I to Ang (1–9), and Ang II to Ang (1–7) which bind the MAS and AT2 receptors forming the ‘protective arm’ of the renin–angiotensin system resulting in vasodilatation, increased nitric oxide synthesis, anti-inflammatory and antifibrotic effects. This counterbalances the ‘classical’ vasoconstrictive, proinflammatory and profibrotic effects of the Ang II/AT1 arm.20–22 (figure 1).

ACE2 also plays an integral role in neutral amino acid transport as a chaperone for the sodium-dependent amino acid transporter B0AT1 in the intestine.23 Mutations in this system lead to Hartnup disease, an autosomal recessive inborn error of metabolism affecting the absorption of non-polar amino acids characterised by pellagra, cerebellar ataxia and psychosis.23

Evidence from mouse models

ACE2 gene knockout (KO)

KO mouse models have provided some evidence for the role of ACE2 but results have been divergent, depending on the mouse background used. For example, in C57BL/6 KO mice a moderate increase in BP was noticed, whereas in 129/SvEv KO mice no difference in BP was noted.24

ACE2 appears to be important for normal cardiac function and contractility.20 The hearts of the KO mice showed clear structural abnormalities with contractility defects and a reduction in BP was also noticed with no hypertrophic or fibrotic changes.20

Other studies reported contrasting findings with no morphological changes and normal cardiac function.21,22 They also noted normal fertility and a normal lifespan in their experimental animals. It is therefore postulated that ACE2 has limited effects on cardiac function and BP control and that other genetic and possibly environmental factors may be important for the function of ACE2. The difference in findings may be due to the mice strains used, and results therefore remain controversial.24

In lung tissue, ACE2 KO mice had significantly worse outcome in induced acute respiratory distress syndrome with increased vascular permeability and pulmonary oedema. Treatment with recombinant ACE2 rescued this phenotype, underlining the protective role of ACE2 in contrast with the disease-promoting effects of ACE, Ang II and AT1 receptor stimulation.23

ACE2 KO in renal disease showed exacerbation of existing hypertension-induced kidney disease.20,24 Furthermore, ACE2 appears to play a protective role in diabetic kidney disease.20,24

Overexpression of ACE2 gene in transgenic models

There are limited data from transgenic models. When overexpressed in heart tissue, ventricular tachycardia and sudden death was observed.26 In the kidney, overexpression of ACE2 appeared to be protective against diabetic kidney disease.77,78 Transgenic mice were also found to be more susceptible to SARS-CoV infection.28

Function of ACE2 and polymorphisms in disease

Cardiovascular system

ACE2 expression was found to be decreased in patients with heart failure and levels correlated with disease severity.29 It was postulated that higher ACE2 levels may be cardioprotective, as cardiac dysfunction was noted in ACE2 KO mice.30 ACE2 deficiency upregulates mediators of atherogenesis and ACE2 suppresses vascular inflammation with subsequent development of atherosclerosis.31 ACE2, via Ang (1–7), increases nitric oxide which has vasodilatory and antithrombogenic effects.32

The apelin peptide family protects against the development of cardiovascular disease. Apelin KO mice have reduced ACE2 messenger RNA and ACE2 protein levels.33 Apelin deficiency can potentially lead to cardiovascular disease including heart failure and hypertension with impaired contractibility and hypertrophy.34 When AT1 was also inhibited in apelin KO mice, the induced phenotype was rescued. This was accompanied by an increase in ACE2 underlining its possible protective traits.34

Studies investigating the effects of single nucleotide polymorphisms (SNPs) of ACE2 in hypertension showed mixed results. A number of SNPs of the ACE2 gene are associated with essential hypertension (EH) in humans, as the gene is located in area on the X chromosome20,35 known to be associated with hypertension disorders on the X-chromosome. ACE2 downregulation results in BP dysregulation.33 ACE2 deletion in rats led to impaired baroreflex sensitivity and autonomic dysfunction.36

ACE2 polymorphisms in dyslipidaemia have also been studied. A variant ACE2 rs4646188 was found to be a potential marker of susceptibility for EH, dyslipidaemia and related ischaemic stroke in Asian communities.37 However, another study found that this variant was not correlated with a dyslipidaemia in Uyghur communities.38 Therefore, variant effects differ in various populations and environmental and genetic factors are important.

Respiratory system

The role of ACE2 in COVID-19 is now well established and there is intense interest in how it influences the unusual pathophysiology seen. Lung ACE2 levels decline with age in rat models18 and this decline is higher in males. This supports the observation that older men are more susceptible to SARS-CoV-2 infection.

Certain variations in ACE2 may increase individual susceptibility to COVID-19 infection, but these are very rare.38 It has been postulated that downregulation of ACE2 may reduce the susceptibility to COVID-19, but in animal models it was found that lower levels of ACE2 were also associated with lung oedema and worsening acute lung injury.39

Endocrine system and metabolism

Some polymorphisms of ACE2 may be useful markers for type 2 diabetes mellitus and some polymorphisms are associated with cardiovascular complications in this setting.40 In the pancreas, ACE2 has glycemia-protective properties,41 and in the kidney low ACE2 levels are associated with worsening diabetic nephropathy.42 Diabetic retinopathy is associated with the activation of the classical arm of the renin–angiotensin system and the proinflammatory, profibrotic and activation of oxidative stress of this arm can be counteracted by ACE2/Ang (1–7).43

ACE2 also plays an important role in the browning of adipose tissue leading to favourable metabolic effects and weight loss.43

Renal system

ACE2 is extensively expressed in tubular epithelial cells and also the vascular components and glomerular epithelium.44 In hypertensive kidney disease, ACE2 levels were decreased.44 Although ACE inhibitors and angiotensin receptor blockers do not affect the enzymatic activity of ACE2, they increase ACE2 gene expression in animal studies.45

In diabetic kidney disease, ACE2 is protective and overexpression of ACE2 in podocytes reduces diabetic kidney disease in animal models.46

Studies investigating the effects of single nucleotide polymorphisms (SNPs) of ACE2 in hypertension showed mixed results. A number of SNPs of the ACE2 gene are associated with essential hypertension (EH) in humans, as the gene is located in area on the X chromosome20,35 known to be associated with hypertension disorders on the X-chromosome. ACE2 downregulation results in BP dysregulation.33 ACE2 deletion in rats led to impaired baroreflex sensitivity and autonomic dysfunction.36

ACE2 polymorphisms in dyslipidaemia have also been studied. A variant ACE2 rs4646188 was found to be a potential marker of susceptibility for EH, dyslipidaemia and related ischaemic stroke in Asian communities.37 However, another study found that this variant was not correlated with a dyslipidaemia in Uyghur communities.38 Therefore, variant effects differ in various populations and environmental and genetic factors are important.

Respiratory system

The role of ACE2 in COVID-19 is now well established and there is intense interest in how it influences the unusual pathophysiology seen. Lung ACE2 levels decline with age in rat models18 and this decline is higher in males. This supports the observation that older men are more susceptible to SARS-CoV-2 infection.

Certain variations in ACE2 may increase individual susceptibility to COVID-19 infection, but these are very rare.38 It has been postulated that downregulation of ACE2 may reduce the susceptibility to COVID-19, but in animal models it was found that lower levels of ACE2 were also associated with lung oedema and worsening acute lung injury.39

Endocrine system and metabolism

Some polymorphisms of ACE2 may be useful markers for type 2 diabetes mellitus and some polymorphisms are associated with cardiovascular complications in this setting.40 In the pancreas, ACE2 has glycemia-protective properties,41 and in the kidney low ACE2 levels are associated with worsening diabetic nephropathy.42 Diabetic retinopathy is associated with the activation of the classical arm of the renin–angiotensin system and the proinflammatory, profibrotic and activation of oxidative stress of this arm can be counteracted by ACE2/Ang (1–7).43

ACE2 also plays an important role in the browning of adipose tissue leading to favourable metabolic effects and weight loss.43

Renal system

ACE2 is extensively expressed in tubular epithelial cells and also the vascular components and glomerular epithelium.44 In hypertensive kidney disease, ACE2 levels were decreased.44 Although ACE inhibitors and angiotensin receptor blockers do not affect the enzymatic activity of ACE2, they increase ACE2 gene expression in animal studies.45

In diabetic kidney disease, ACE2 is protective and overexpression of ACE2 in podocytes reduces diabetic kidney disease in animal models.46

Studies investigating the effects of single nucleotide polymorphisms (SNPs) of ACE2 in hypertension showed mixed results. A number of SNPs of the ACE2 gene are associated with essential hypertension (EH) in humans, as the gene is located in area on the X chromosome20,35 known to be associated with hypertension disorders on the X-chromosome. ACE2 downregulation results in BP dysregulation.33 ACE2 deletion in rats led to impaired baroreflex sensitivity and autonomic dysfunction.36

ACE2 polymorphisms in dyslipidaemia have also been studied. A variant ACE2 rs4646188 was found to be a potential marker of susceptibility for EH, dyslipidaemia and related ischaemic stroke in Asian communities.37 However, another study found that this variant was not correlated with a dyslipidaemia in Uyghur communities.38 Therefore, variant effects differ in various populations and environmental and genetic factors are important.

Respiratory system

The role of ACE2 in COVID-19 is now well established and there is intense interest in how it influences the unusual pathophysiology seen. Lung ACE2 levels decline with age in rat models18 and this decline is higher in males. This supports the observation that older men are more susceptible to SARS-CoV-2 infection.

Certain variations in ACE2 may increase individual susceptibility to COVID-19 infection, but these are very rare.38 It has been postulated that downregulation of ACE2 may reduce the susceptibility to COVID-19, but in animal models it was found that lower levels of ACE2 were also associated with lung oedema and worsening acute lung injury.39

Endocrine system and metabolism

Some polymorphisms of ACE2 may be useful markers for type 2 diabetes mellitus and some polymorphisms are associated with cardiovascular complications in this setting.40 In the pancreas, ACE2 has glycemia-protective properties,41 and in the kidney low ACE2 levels are associated with worsening diabetic nephropathy.42 Diabetic retinopathy is associated with the activation of the classical arm of the renin–angiotensin system and the proinflammatory, profibrotic and activation of oxidative stress of this arm can be counteracted by ACE2/Ang (1–7).43

ACE2 also plays an important role in the browning of adipose tissue leading to favourable metabolic effects and weight loss.43

Renal system

ACE2 is extensively expressed in tubular epithelial cells and also the vascular components and glomerular epithelium.44 In hypertensive kidney disease, ACE2 levels were decreased.44 Although ACE inhibitors and angiotensin receptor blockers do not affect the enzymatic activity of ACE2, they increase ACE2 gene expression in animal studies.45

In diabetic kidney disease, ACE2 is protective and overexpression of ACE2 in podocytes reduces diabetic kidney disease in animal models.46
Neurological system
The ability of ACE and ACE2 to cleave amyloid-β-peptidase and the use of inhibitor drugs of the renin–angiotensin system and their role in the development Alzheimer’s disease have been investigated with no concrete conclusions at this stage. 46

Gastrointestinal system
ACE2 is important in regulating intestinal amino acid transport and plays a vital role in the expression of antimicrobial peptides and prevention of gut dysbiosis. 47 ACE2 deficiency resulted in increased susceptibility for intestinal inflammation. 47 In the liver, ACE2 is protective against the development of fibrosis via Ang (1–7). 48 In ACE2 KO mice, there was significant worsening of liver fibrosis in chronic induced liver conditions. Interestingly, this was not observed in acute liver injury. 49

Neoplasms
Overexpression of ACE2 and DNA hypomethylation was observed in tumours including colon adenocarcinoma, kidney papillary cell adenocarcinoma, pancreatic, rectum, stomach and rectum adenocarcinoma. 50 Lung adenocarcinoma had been investigated with no concrete conclusions at this stage. 50

Pregnancy and fertility
ACE2 and Ang (1–7) are present in uteroplacental tissue and are important in placentation of normal pregnancy via vasoactive regulatory action. ACE2 and Ang (1–7) expression is similar in uncomplicated and pre-eclamptic pregnancies. 51 AOZ co-acknowledged this study, and ASZ revised and amended the revisions of the first draft and figures and prepared the final manuscript and references. Images created with BioRender.com.

CONCLUSION
ACE2 plays a complex role in disease that has relevance beyond the cardiovascular and respiratory systems. Its role in the pathophysiology of COVID-19 is a source of ongoing research and makes it an attractive possible therapeutic target. Of recent interest is the effect of tobacco smoking on ACE2 expression in the lung which implies that smoking could increase the susceptibility to lung infection by SARS-CoV-2. 52

It is clear that further studies of its genetic and physiological roles will be required to fully understand how it could be therapeutically modulated in disease.

Handling editor Des Richardson.

Contributors OW wrote the first and subsequent drafts and prepared the figures. 5Wiese OA, Barnes JS, Côté J, et al. A novel angiotensin-converting enzyme – related to angiotensin-1-9. Circ Res 2000;87:1–9.

2 Tipnis SR, Hooper NM, Hyde K, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000;275:33238–43–43. 3 Jin Y, Yang H, Ji W, et al. Virolology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12:372.

4 Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.

5 WHO director-general’s opening remarks at the media briefing on COVID-19, 2020.

6 Johns Hopkins University coronavirus resource center, 2020.

7 Devaux CA, Rollin J-M, Raoult D. ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Infect 2020;5:345–35.

8 Luo Y, Liu C, Guan T, et al. Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in South Xinjiang. Hypertens Res 2019;42:681–9.

9 Burrell UM, Harrap SB, Velkoska E, et al. The ACE2 gene: its potential as a functional candidate for cardiovascular disease. Clin Sci 2013;124:65–76.

10 Patel SK, Velkoska E, Freeman M, et al. From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Front Physiol 2014;5:227–12.

11 Liu J, Ji H, Zheng W, et al. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent. Biol Sex Differ 2010;1:6.

12 James GD, Sealey JE, Müller F, et al. Renin relationship to sex, race and age in a normotensive population. J Hypertens Suppl 1986;4:3387–9.

13 Imai Y, Kuba K, Ohto-Nakano T, et al. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J 2010;74:405–10.

14 Turner AL. Chapter 25: ACE2 cell biology, regulation, and physiological functions. In: The protective arm of the renin angiotensin system (RAS): functional aspects and therapeutic implications. Elsevier, 2015.

15 Ferrario CM, Jessup J, Gallagher FE, et al. Effects of renin-angiotensin system blockade on renal angiotensin (1–7) forming enzymes and receptors. Kidney Int 2005;68:2189–96.

16 Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol 2008;75:751–6.

17 Zhang H, Wada J, Hida K, et al. Collectin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem 2001;276:17132–9.

18 Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol 2020;73:366–9.

19 Battle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci 2020;134:543–5.

20 Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822–8.

21 South AM, Diz DJ, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol 2020;318:H1084–90.

22 Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450–4.

23 Singer D, Camargo SMR. Collectin and ACE2 in renal and intestinal amino acid transport. Channels 2011;5:10–23.

24 Guryev SB, Alleda A, Le TH, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006;116:2218–25.

25 Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112–6.

26 Donoghue M, Wakimoto H, Maguire CT, et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 2003;35:1043–53.

27 Nadarajah R, Milagres R, Dilauro M, et al. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 2012;82:292–303.

28 Yang Z-H, Deng W, Tong Z, et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp Med 2007;57:450–9.

29 Epelman S, Shrestha K, Troughton RW, et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 2009;15:565–71.

ORCID iD
Tahir S Pillay http://orcid.org/0000-0002-9982-9710
Molecules in pathogenesis

30 Oudit GY, Kassi Z, Jiang C, et al. SARS-CoV-2 modulation of myocardial ACE2 expression and inflammation in patients with SARS. *Eur J Clin Invest* 2009;39:618–25.
31 Thomas MC, Pickering RJ, Tsorotes D, et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. *Circ Res* 2010;107:888–97.
32 Santos RAS, Sampaio WD, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/Mas axis of the renin-angiotensin system: Focus on Angiotensin-(1-7). *Physiol Rev* 2018;98:505–53.
33 Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. *Circ Res* 2020;126:1456–74.
34 Sato T, Suzuki T, Watanabe H, et al. Apelin is a positive regulator of ace2 in failing hearts. *J Clin Invest* 2013;123:5203–11.
35 Chen YY, Liu D, Zhang P, et al. Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors. *J Hum Hypertens* 2016;30:766–71.
36 Xie X, Xuoding X, Chen J, et al. Age- and gender-related difference of ACE2 expression in rat lung. *Life Sci* 2006;78:2499–2511.
37 Pan Y, Wang T, Li Y, et al. Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China. *Lipids Health Dis* 2018;17:241–9.
38 Stawiski EW, Diwanji D, Suryamohan K, et al. Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility. *bioRxiv* 2020.
39 Kuba K, Imai Y, Rau S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 2005;11:875–9.
40 Liu C, Li Y, Guan T, et al. ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus. *11 medical and health sciences 1103 clinical sciences. Cardiovas Diabetol* 2018;17.
41 Pedersen KB, Chhabria KI, Nguyen V, et al. The transcription factor HNF1αx induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from evolutionarily conserved promoter motifs. *Biochim Biophys Acta* 2013;1829:1225–35.
42 Reich HN, Oudit GY, Penninger JM, et al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. *Kidney Int* 2008;74:1610–6.
43 Verma A, Shan Z, Lei B, et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. *Mol Ther* 2012;20:28–36.
44 Soler ML, Wysocki J, Battle D. ACE2 alterations in kidney disease. *Nephrol Dial Transplant* 2013;28:2687–97.
45 Jessup JA, Gallagher PE, Averill DB, et al. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. *Am J Physiol Heart Circ Physiol* 2006;291:H2166–72.
46 Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer’s disease: progress toward disease prevention and treatment? *J Alzheimers Dis* 2018;62:1443–6.
47 Hashimoto T, Periot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. *Nature* 2012;487:477–81.
48 Osterreicher CH, Taura K, De Minicis S, et al. Angiotensin-converting enzyme 2 inhibits liver fibrosis in mice. *Hepatology* 2009;50:929–38.
49 Chai P, Yu J, Ge S, et al. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis. *J Hematol Oncol* 2020;13:43.
50 Valdés G, Neves LAA, Anton L, et al. Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. *Placenta* 2006;27:200–7.
51 Brosnihan KB, Neves LAA, Joyner J, et al. Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. *Hypertension* 2003;42:749–53.
52 Cai G, Bossé Y, Xiao F, et al. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. *Am J Respir Crit Care Med* 2020;201:1557–9.
53 Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. *Int J Hypertens* 2012;2012:307315.